Capstone Investment Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Capstone Investment Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-29,554	Closed	-$281K	–	1671
2026 Q1	$281K	Buy	+29,554	New	+$230K	﹤0.01%	1391
2025 Q4	–	Sell	-18,358	Closed	-$139K	–	1610
2025 Q3	$139K	Buy	+18,358	New	+$153K	﹤0.01%	1859
2024 Q3	–	Sell	-26,742	Closed	-$165K	–	1919
2024 Q2	$165K	Buy	+26,742	New	+$148K	﹤0.01%	1804
2024 Q1	–	Sell	-18,650	Closed	-$112K	–	2342
2023 Q4	$112K	Buy	+18,650	New	+$108K	﹤0.01%	1925
2023 Q3	–	Sell	-17,164	Closed	-$121K	–	2099
2023 Q2	$121K	Buy	+17,164	New	+$138K	﹤0.01%	1665

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Capstone Investment Advisors's BCRX Position: Q2 2026 in Review

Capstone Investment Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 29,554 shares — an estimated $281K sold.

Capstone Investment Advisors first reported a position in BCRX in Q2 2023 and held it in 5 quarters. The position peaked at $281K in Q1 2026. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Capstone Investment Advisors reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Capstone Investment Advisors sold 29,554 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $281K.
Capstone Investment Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2023 and held it in 5 quarters.
Capstone Investment Advisors's BioCryst Pharmaceuticals position peaked at $281K in Q1 2026.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.